Quantification of Genotoxic Impurities by HPLC in Active Pharmaceutical Ingredient Lorazepam.

A simple and selective reversed-phase high performance liquid chromatography method was developed and validated for the quantification of 4-chloroaniline, 2-chloro-N-(4-chloro-2-(2-chlorobenzoyl)phenyl)acetamide and 2-iodo-N-(4-chloro-2-(2-chlorobenzoyl)phenyl)acetamide in lorazepam. 4‑Chloroaniline is used as a raw material and 2-chloro-N-(4-chloro-2-(2-chlorobenzoyl)phenyl)acetamide and 2-iodo-N-(4-chloro-2-(2-chlorobenzoyl)phenyl)acetamide are formed as intermediates in the synthesis of anxiety disorder active pharmaceutical ingredient lorazepam. This method provided excellent sensitivity and a typical target analyte level of 150 ppm. This method was developed on an Agilent poroshell 120 EC-C18 (100 × 4.6 mm, 4 µm) column and a photo diode array detector. The proposed method is specific, linear, accurate and precise. The calibration curve was linear over the concentration range of LOQ to 120% with a correlation coefficient of 0.99. This method has low limits of detection and quantification for all the analytes. Accuracy was observed within the range of 85–115% for all the analytes. The developed method was validated as per the ICH guidelines in terms of specificity, precision, limit of detection, limit of quantification, linearity range and accuracy. [ABSTRACT FROM AUTHOR]